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Abstract
Background: People with severe mental ill health are more likely to smoke than those in the general population. It
is therefore important that effective smoking cessation strategies are used to help people with severe mental ill
health to stop smoking. This study aims to assess the effectiveness and cost –effectiveness of smoking cessation
and reduction strategies in adults with severe mental ill health in both inpatient and outpatient settings.
Methods: This is an update of a previous systematic review. Electronic databases were searched during September
2016 for randomised controlled trials comparing smoking cessation interventions to each other, usual care, or
placebo. Data was extracted on biochemically-verified, self-reported smoking cessation (primary outcome), as well
as on smoking reduction, body weight, psychiatric symptom, and adverse events (secondary outcomes).
Results: We included 26 trials of pharmacological and/or behavioural interventions. Eight trials comparing
bupropion to placebo were pooled showing that bupropion improved quit rates significantly in the medium and
long term but not the short term (short term RR = 6.42 95% CI 0.82–50.07; medium term RR = 2.93 95% CI 1.61–5.
34; long term RR = 3.04 95% CI 1.10–8.42). Five trials comparing varenicline to placebo showed that that the
addition of varenicline improved quit rates significantly in the medium term (RR = 4.13 95% CI 1.36–12.53). The
results from five trials of specialised smoking cessation programmes were pooled and showed no evidence of
benefit in the medium (RR = 1.32 95% CI 0.85–2.06) or long term (RR = 1.33 95% CI 0.85–2.08). There was
insufficient data to allowing pooling for all time points for varenicline and trials of specialist smoking cessation
programmes. Trials suggest few adverse events although safety data were not always reported. Only one pilot
study reported cost effectiveness data.
Conclusions: Bupropion and varenicline, which have been shown to be effective in the general population, also
work for people with severe mental ill health and their use in patients with stable psychiatric conditions. Despite
good evidence for the effectiveness of smoking cessation interventions for people with severe mental ill health, the
percentage of people with severe mental ill health who smoke remains higher than that for the general population.
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Background
The physical health of people with severe mental ill
health (SMI) is poor, with people with a diagnosis of
SMI dying 20–25 years earlier than those in the general
population [1]. Smoking is one of the most important
modifiable risk factors that contributes to this excess
mortality [2]. People with SMI tend to smoke more
heavily and extract more nicotine from cigarettes than
smokers without mental health problems [3], and up to
70% of people with SMI smoke [4].
Whilst the percentage of people who smoke in the gen-
eral population has been steadily declining, the percentage
of people with SMI who smoke has not seen a similar de-
cline [5]. Despite this, when questioned, the percentage of
people with SMI who are interested in cutting down or
quitting smoking is similar to that of the general population
[6]. In 2010 a systematic review was conducted to establish
the clinical and cost effectiveness of smoking cessation and
reduction strategies for people with SMI to determine the
most successful strategies such as the use of pharmacother-
apy (e.g. nicotine replacement therapy, varenicline, bupro-
pion) or behavioural interventions [7]. In the United
Kingdom, following the publication of guidance issued by
the National Institute of Health and Care Excellence
(NICE) Guidance PH 48 in 2013 [8], a number of mental
health trusts have decided to go smoke free and encourage
people with SMI to give up or cut down on their smoking.
We have therefore decided to update the 2010 review with
the additional inclusion of e-cigarettes as a smoking cessa-
tion strategy to provide up to date information on the most
effective and cost-effective strategies to help people with
SMI cut down or quit smoking.
Objectives
To assess the effectiveness and cost-effectiveness of smok-
ing cessation and reduction strategies in adults with severe
mental ill health.
Methods
Search strategy
The protocol for this review has been registered on the
PROSPERO register of systematic reviews (http://www
.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD
42015029455).
An electronic search strategy based on that used in our
previous review, combining search terms for severe mental
ill health, smoking cessation and randomised controlled tri-
als, adapted from terms developed by the Cochrane groups
for schizophrenia and tobacco addiction was used to search
the following database for potentially relevant studies:
MEDLINE (PubMed), EMBASE, PsycINFO, CINAHL,
Health Management Information Consortium (HMIC) and
CENTRAL.
The search strategy was limited to the inception year
of each database until September 2016. An example of
the search strategy is shown in an additional word file
(see Additional file 1).
Searching other resources.
Reference lists of all identified studies and existing reviews
were checked for additional potentially relevant studies.
Inclusion criteria
Types of studies
Randomised controlled trials (RCTs), including cluster-
randomised controlled trials, that assess the effects of
smoking cessation and reduction interventions in people
with severe mental ill health were included. Studies
conducted in any country and in either in-patient or out
patient settings were eligible for inclusion. Studies that are
not published in English were excluded.
Types of participants
Participants were adults aged 18 years and above who had
been diagnosed with SMI. We defined SMI as schizophre-
nia or other psychotic disorders, bipolar disorder and de-
pression with psychotic features. We have not included
personality disorder, severe anxiety disorder, post traumatic
stress disorder (PTSD), major depression or autism in this
review. We have based this classification on diagnoses that
would typically be included on a UK primary care SMI
register [9]. Diagnosis needed to be made by using Inter-
national Classification of Disease (ICD10 F20–29 and F30–
31) or Diagnostic and Statistical Manual (DSM IV 295.x,
296.x and 297.x) criteria.
Studies involving participants who had a problem with
substance abuse (other than nicotine addiction) without
any other mental disorder, or whose participants had
learning disability, dementia, other neurocognitive disor-
ders or terminal illness were not included in this review.
Types of interventions
Trials of all types of smoking cessation and reduction strat-
egies, (behavioural or pharmacological as monotherapy or
in combination) compared to each other, placebo, usual
care or to no intervention were included, including trials of
very brief advice. Behavioural interventions include on-to-
one programmes, group programmes, and telephone coun-
selling. Pharmacotherapy includes products licensed for
smoking cessation e.g. nicotine replacement therapy (NRT),
varenicline, nortriptyline, and bupropion. Trials in which
electronic cigarettes (‘e-cigarettes’) have been used as a
smoking cessation aid were also included. Studies looking
at ‘implementation of a smoke-free environment’ as an
intervention were excluded. Behavioral interventions were
classed as ‘group’ or ‘individual’ therapy.
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Types of outcome measure
The primary outcome measure was biochemically verified
self-reported smoking cessation. Accepted methods of
biochemical verification were expired carbon monoxide (CO
level of <10 ppm (p.p.m.), salivary cotinine <15 ng/ml,
urinary cotinine <50 ng/ml or serum cotinine <15 ng/ml. All
follow-up times were included and categorised as short-term
quit if less than or up to four weeks, mid term quit for up to
six months, and long-term quit if longer than six months.
Participants lost to follow up were treated as ‘still smokers’.
The secondary outcomes were:
1. Smoking reduction; as no acceptable standard exists
for its measurement, any measure was acceptable as
long as it was verified by biochemical assay
2. Change in body weight
3. Change in psychiatric symptoms (any validated
symptom scale)
4. Adverse events
Selection of included studies and data extraction
Two authors independently screened 10% of the titles and
abstracts of publications identified by the search strategy.
Results from this initial screening were compared to check
the level of agreement between the two authors over which
studies should proceed to full text screening. Both authors
were in agreement over which texts should proceed to full
text screening therefore one author continued to screen the
remaining studies. All studies that were not applicable
according to our inclusion criteria were discarded. The full
text of the remaining references was obtained.
Two authors independently decided whether the studies
meet the inclusion criteria with any disagreements
resolved through discussion with a third author.
Data extraction
Two authors independently extracted data from the in-
cluded studies. Any disagreements were resolved through
discussion with a third author where necessary.
Any missing data, relating to the primary outcome only,
was sought by contacting the Investigators and/or corre-
sponding authors of primary studies.
Assessment of risk of bias in included studies
The methodological quality of included trials was assessed
independently by two reviewers using the Cochrane’s tool
for assessing risk of bias, [10] which assesses the following
domains:
1. Sequence generation (selection bias)
2. Allocation concealment (selection bias)
3. Blinding of participants and personnel
(performance bias)
4. Blinding of outcome assessment (detection bias);
5. Incomplete outcome data (attrition bias)
6. Selective outcome reporting (reporting bias)
7. Other potential sources of bias
Each of the domains was scored as ‘high’, ‘low’ or
‘unclear’ risk of bias, following criteria outlined in Chapter
8 of the Cochrane Handbook for Systematic Reviews of
Interventions [10].
Data synthesis
A narrative overview of study design features, study popu-
lations, outcomes, risk of bias and study results is given.
For smoking cessation data, we present risk ratios with
95% confidence intervals as per our previous review [7].
Where interventions and comparisons were sufficiently
similar we conducted a meta-analysis using RevMan (ver-
sion 5.3, Review Manager (RevMan) [Computer program].
Version 5.3. Copenhagen: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2014). We performed standard
pairwise meta-analysis for every comparison that contained
at least two studies and used a random-effects model if
studies were statistically heterogeneous as measured by I2
(I2 ≥ 50%); otherwise we used a fixed-effect model.
Absolute quit rate was taken as the proportion of partici-
pants who met criteria for abstinence out of the number
randomised to that group.
Unit of analysis issues
The unit of analysis was the individual.
Results
Of the 1312 records identified 106 full texts were screened
(Fig. 1). Of these 28 (based on 26 studies) involving 1978
participants met the inclusion criteria [11–38]; 18 more
studies than in our previous review. The reasons for ineli-
gibility are shown in Fig. 1, with the most common reason
being that the study was not a randomised controlled trial.
Study characteristics
Study characteristics are given in Table 1. No cluster
RCTs were identified in this review. The sample size of
the studies ranged from five participants [22, 37] to 298
participants [18]. The majority of the studies recruited
participants who were outpatients (n = 20), one study
recruited solely from an inpatient setting [29], and one
study recruited from a mixture of inpatients and outpa-
tients [35] the remaining 4 studies did not clearly state
whether the participants were inpatients or outpatients.
Sixteen of the studies were conducted in the United
States, two in Australia, one in Taiwan, one in England one
in the United States, Israel and China and one in the
United States and Canada. In four studies the country was
not clearly stated.
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The majority of the studies recruited participants with
schizophrenia or schizoaffective disorder (n = 21), with
three studies recruiting participants with bipolar disorder,
and two studies included participants with schizophrenia,
schizoaffective disorder or bipolar disorder. In eight of
the studies it was a study requirement that the partic-
ipants had stable symptoms, in three studies it was a
requirement that participants were on a stable dose
of medication and in six studies it was a requirement
that participants has stable symptoms and were on a
stable dose of medication. Nine studies did not state
whether the participants were clinically stable or were
on a stable dose of medication.
In just over half of the studies the participants had
expressed a willingness to quit smoking (n = 12), in one
study participants were excluded if they were planning on
quitting in the next 30 days [36] and in the remaining 12
studies participants’ views on quitting were not stated. No
study stated that it was recruiting participants with no inter-
est in quitting smoking.
Nine of the studies used an intention to treat analysis,
one used a per protocol analysis [36] and 16 studies did not
report whether or not they used an intention to treat
analysis.
Description of the interventions
The included studies covered a range of interventions
(Table 1). Nine studies explored the effects of the prescrip-
tion of bupropion, six studies the prescription of vareni-
cline and one study the prescription of nicotine
replacement therapy (NRT). The varenicline studies all
followed a standard dosing schedule whereas the dose in
the bupropion studies ranged from 150 mg once per day
to150 mg twice per day. Five studies explored the effects of
a specialist smoking cessation programme for people with
Fig. 1 Prisma diagram
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Table 1 Study characteristics
Study/design Population Interventions Smoking abstinence outcomes Secondary outcomes
Complex interventions
Baker
2006 [18, 38]
(including data
from Baker 2010)
RCT
298 clinically stable adult outpatients
with ICD diagnosis of psychotic disorder
who expressed an interest in quitting
smoking and smoke ≥15 cigarettes per day.
Australia
52% male, ethnicity not stated.
1. Individual motivational interviewing/CBT
2. Usual care
Intervention consisted of 8 × 1 hour
sessions of manualised motivational
interviewing and CBT over 10 weeks.
Continuous abstinence self report
verified by expired CO < 10 ppm
at 3,6, 12 months and 4 years
7 day point prevalence smoking
abstinence verified by expired
CO <10 ppm at 3, 6 12 months
and 4 years
Change in psychiatric
symptoms (BDI, BPRS,
SF-12, STAI)
Baker
2015 [32]
RCT
235 adult outpatients who expressed
an interest in quitting smoking with
ICD diagnosis of psychotic disorder and
Smoking ≥15 cigarettes per day and
with stable symptoms. Australia
59% male, 84% Australian born.
1. Healthy lifestyle intervention
(individual)
2. Telephone intervention
Healthy lifestyle intervention consisted
of manualised motivational interviewing
and CBT delivered as a single 90 min
sessions followed by 7 × 1 h sessions
weekly then 3 fortnightly 1 h sessions
then monthly 1 hour sessions for 6 months.
The telephone intervention consisted
of 1 face to face meeting followed by
up to 16 × 10 minute manualised
telephone sessions
7 day point prevalence smoking
abstinence verified by expired
CO <10 ppm at 15 weeks and
12 months verified by expired
CO measure
Number of cigarettes per day
FTND
Change in psychiatric
symptoms (BBRS-24, BDI,
SF-12 mental component)
George
2000 [12]
RCT
45 participants with DSM IV schizophrenia
or schizoaffective disorder with a FTND
score of ≥5 United States 67% male,
62% white.
1. ALA group programme + NRT patch
2. Specialised group programme + NRT patch
*21 mg for 6 weeks then 14 mg for 2 weeks
then 7md for 2 weeks
ALA group consisted of 3 weekly 60 min
manualised sessions of group counselling
Specialised programme consisted of 3 weeks
of 1 h motivational enhancement then 7
weeks 1 h of psychoeducation. All manualised
7 day point prevalence abstinence
at week 10, and 26 verified by
expired CO <10 ppm.
Continuous abstinence in last 4
weeks of treatment
Change in psychiatric
symptoms (AIMS, BDI,
PANSS, WEPS)
Gilbody
2015 [33]
RCT
97 adult outpatients with DSM IV
schizophrenia, schizoaffective disorder or
bipolar disorder who expressed a desire
to cut down or quit smoking and smoked
≥10 cigarettes per day. England 60% male,
87% white.
1. Bespoke intervention
2. Usual care
Intervention consisted of 8-10 × 30 min
maunalised sessions tailored to the
participants needs.
Smoking cessation at 12 months
(CO ≤ 10 ppm)
FTND
Number of cigarettes per day
Change in psychiatric
symptoms (SF-12, PHQ-9)
Smith
2015 [34]
RCT
33 outpatients with DSM IV schizophrenia
or schizoaffective disorder 73% male,
30% white.
1. 5 sessions of transcranial direct current
stimulation
2. 5 sessions of sham treatment
Self report number of cigarettes
smoked and expired CO I week
after final treatment session
Urges to smoke
PANSS and PSYCHRATS
hallucination scale
Steinberg
2003 [15]
RCT
78 outpatients with DSM IV schizophrenia
or schizoaffective disorder smoking ≥10
cigarettes per day United States
68% male, 77% white.
1. Motivational interviewing (individual)
2. Psychoeducational intervention
(individual)
3. Control
Motivational interviewing consisted
of 1 × 40 minute session.
Expired CO at 1 week and 1 month
Number of cigarettes per day
Heaviness of smoking
Contemplation ladder
FTND
Importance of quitting
Confidence in ability to quit
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Table 1 Study characteristics (Continued)
Psychoeducation consisted of 1 × 40
minute session
Control consisted of 1 5 min session.
Steinberg
2016 [36]
RCT
98 outpatients with DSM IV schizophrenia,
schizoaffective disorder or Bipolar I 46%
male, 61% white.
1. Motivation interviewing 1 × 45 min
personalised session
2. Interactive education 1 × 45 min
non personalised session
Motivational interviewing 1 45 min
session manualised.
Interactive education consisted of
1 × 45 min manualised session
Expired CO at 1 month
Motivation to quit
Williams
2010 [23]
RCT
100 adult outpatients with DSM IV
schizophrenia or schizoaffective disorder
who Smoke ≥10 cigarettes per day and
were willing to try and quit smoking.
United States
64% male, 66% white.
1. Treatment of nicotine addiction in
schizophrenia + nicotine patch
(individual)
2. Medication management +
nicotine patch
3. (individual)
*21 mg for 12 weeks and 14 mg
for 4 weeks
TANS consisted of 24 × 45 min
sessions over 26 weeks of manualised
motivational interviewing.
MM consisted of 9 × 20 min sessions
of manualised active education.
7 day point prevalence abstinence
at 3, 6 and 12 months verified by
expired CO <10 ppm.
Continuous abstinence at 3 months.
Change in psychiatric
symptoms (BDI, PANSS)
Wing
2012 [28]
RCT
15 DSM-IV schizophrenia or schizoaffective
disorder, smoking ≥10 cigarettes per day
for 3 years or more with expired CO ≥
10 ppm and FTND score ≥ 4 and motivated
to quit within the next month.
Ethnicity and gender not reported.
1. Trans cranial magnetic stimulation +
weekly group therapy and nicotine
patch (21 mg)
2. Sham + weekly group therapy and
nicotine patch (21 mg)
Weekly (for 10 weeks) Smoking self
report verified by expired CO.
Tiffany questionnaire for smoking urges
Change in psychiatric
symptoms (PANSS)
Adverse events
Bupropion studies
Evins
2001 [13, 16]
(including data
from Evins 2004)
RCT
19 DSM IV schizophrenia outpatients on a
stable dose of antipsychotic medication for
at least 4 weeks who smoke at least half
a pack of cigarettes per day and express
a wish to quit smoking
United States
61% male, 89% white.
1. Bupropion (150 mg per day) + CBT
Quit Smoking Group
2. Placebo + CBT Quit Smoking group
7 day point prevalence abstinence
verified by expired CO < 9 ppm or
serum cotinine <14 ng/ml at 12
and 24 weeks and 2 years
Significant smoking reduction at12,
24 weeks and 2 years defined by
≥30% reduction in expired CO and
≥50% reduction in number of
cigarettes per day
Change in psychiatric
symptoms (BPRS, SANS,
HamD, AIMS, Hillside
Akathisia Scale, SAS)
Evins
2005 [17]
RCT
19 DSM-IV schizophrenia or schizoaffective
disorder outpatients and smokes 10
cigarettes per day with stable symptoms
and on a stable dose of antipsychotic for
>30 days HAM-D
score ≤ 20 and willing to set a quit date
within 4 weeks.
United states
1. Bupropion (150 mg) + behavioural
therapy intervention
2. Placebo + behavioural therapy
intervention
7 day point prevalence abstinence
at week and week 4, 12 and 24
verified by expired CO <9 ppm.
4 week continuous abstinence at
week 24
Number of cigarettes smoked
per day
Change in psychiatric
symptoms (SANS, Ham-D,
Ham-A, PANSSS,
SAS, Barnes akathisia scale)
Adverse events
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Table 1 Study characteristics (Continued)
68% male, ethnicity not reported.
Evins
2007 [19]
RCT
51 adult outpatients DSM-IV Schizophrenia,
capacity to consent, smokes 10 cigarettes
per day with stable symptoms and on a
stable dose of antipsychotic for 30 days
and willing to set a quit date within
4 weeks
United States
57% male, ethnicity not reported.
1. Bupropion (150 mg 1 x daily 7 days
then 150 mg 2× daily thereafter) +
transdermal nicotine patch, nicotine
polacrilex gum and CBT
2. Placebo + transdermal nicotine patch,
nicotine polacrilex gum and CBT
21 mg/d 4 weeks, 21 mg/d 2 weeks
then 7 mg/d 2 weeks
2 mg as needed up to 18 mg/d
7 day point prevalence abstinence
at week12, 24 and 52 verified by
expired CO <8 ppm.
4 week continuous abstinence at
week 8, 12, 24 and 52.
Change in psychiatric
symptoms (SANS, Ham-D,
STAI, PANSSS)
Fatemi
2013 [30]
RCT
24 clinically stable DSM-IV schizophrenia
or schizoaffective disorder, smoking ≥10
cigarettes per day expressing a motivation
to quit or reduce smoking.
United States
Ethnicity and gender not reported.
1. Bupropion + antismoking counselling
2. Varenicline + antismoking counselling
3. Placebo + antismoking counselling
Self report abstinence verified
by CO
Serum and urine levels of nicotine
and cotinine
Change in psychiatric
symptoms (BPRS, SAPS,
SANS, BDI, CSSRS, WISDM,
MNWS)
Adverse events
George
2002 [14]
RCT
32 clinically stable adult outpatients on
a stable dose of medication with DSM IV
schizophrenia or schizoaffective disorder
smoking ≥10 cigarettes per day with
expired CO > 10 ppm, plasma cotinine
>150 ng/ml and scored ≥5 on FTND
and ≥3 on an assessment measure of
self-reported motivation indicating a
strong desire to quit smoking. US
56% male, 63% white.
1. Bupropion (150 mg 2× day) +
specialised schizophrenia smoking
cessation program
2.Placebo +specialised schizophrenia
smoking cessation program
7 day point prevalence abstinence
at week 10, and 36 verified by
expired CO <10 ppm.
Tiffany questionnaire for smoking
urges
Change in psychiatric
symptoms (AIMS, BDI,
PANSS, WEPS)
George
2008 [21]
RCT
58 clinically stable outpatients with DSM
IV schizophrenia or schizoaffective
disorder on a stable dose of antipsychotic
medication and smoking ≥10 cigarettes
per day with expired CO > 10 ppm and
scored ≥7 on the contemplation ladder
United States
60% male, 48% white.
1. Bupropion + manualised group
behavioural therapy + NRT patch (21 mg)
2. Placebo + manualised group
behavioural therapy NRT patch (21 mg)
150 mg per day days 1–3 and
150 mg 2 x day thereafter
7 day point prevalence abstinence
at week 10, and 26 verified by
expired CO <10 ppm.
4 week continuous abstinence
at week 10.
Change in psychiatric
symptoms (BDI, PANS)
Adverse events
Weinberger
2008 [22]
RCT
5 clinically stable DSM-IV Bipolar disorder
I outpatients smoking ≥10 cigarettes
per day with expired CO ≥ 10 ppm
United States
40% male, 100% white.
1. Bupropion + manualised group
behavioural therapy
2. Placebo + manualised group
behavioural therapy
(Days 1–3 75 mg 1 x day, days 4–7
150 mg 1 x day and 150 mg 2×
day thereafter)
Abstinence at 10 weeks verified
by expired CO <10 ppm.
Change in psychiatric
symptoms (YMRS, BDI,
Ham-D)
Adverse events
Weiner
2012 [25]
RCT
41 clinically stable adult outpatients
with DSM IV schizophrenia or
schizoaffective disorder who
Smoke ≥10 and scored ≥ x on FTND
United States
79% male. 72% white.
1. Bupropion + group support
programme
2. Placebo + group support programme
(Days 1–3150 mg 1 x day and 150
mg 2× day thereafter)
Complete abstinence at 15 weeks
defined by expired CO < 10 ppm
at last 4 study visits.
Complete abstinence at 6 months
and 12 months self-report verified
by CO < 10 ppm
Change in psychiatric
symptoms (BPRS, SANS, SAS)
Adverse events
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Table 1 Study characteristics (Continued)
7 day point prevalence abstinence
at 15 weeks verified by CO <
10 ppm FTND
Tidey
2011 [24]
RCT
57 clinically stable adult outpatients
with DSM IV schizophrenia or
schizoaffective disorder on a stable
dose of psychoactive medication who
Smoke ≥20 cigarettes per day and
scored ≥6 on FTND and ≥4 on the
contemplation ladder indicating some
interest in quitting smoking
United states
71% male, 75% white.
1. Contingent + Bupropion
(150 mg per day days 1–3 and
150 mg 2 x day thereafter)
2. Contingent + placebo
3. Bupropion (150 mg per day days
1–3 and 150 mg 2 x day thereafter)
+ non-contingent
4. Placebo +non contingent
Non contingent = $25 dollar store card
Contingent = $25 store card
plus bonuses
Cotinine in urine
CO breath measure
Number of cigarettes per day
At weeks 1,2,3 and 4
Change in psychiatric
symptoms (PANSS,
UPDRS, AIMS)
Varenicline studies
Chengappa
2014 [31]
RCT
60 adult outpatients with DSM-IV
bipolar disorder on a stable dose
of medication.
Smoking ≥10 cigarettes per day
with expired CO ≥ 10 ppm
United States
Ethnicity and gender not reported.
1. Varenicline + smoking cessation
counselling
2. Placebo + smoking cessation
counselling1 × 0.5 mg per day
days 1–3, 0.5 mg 2× per
day days 4–7 then 1 mg 2× per
day thereafter
7 day point prevalence smoking
abstinence verified by expired CO
<10 ppm at 12 weeks and
24 weeks
Continuous 4 week abstinence
at 12 weeks
Change in Psychiatric
symptoms (YMRS, MADRS,
HARS, CGI)
Adverse events
Smith
2016 [35]
RCT
87 adult inpatients or outpatients
with DSM IV schizophrenia or
schizoaffective disorder who smoke
at least 6 cigarettes per day or in
the case of inpatients had flouted
the smoking ban on several occasions.
United States, Israel and China
85% male, 31% white.
1. Varenicline + smoking prevention
counselling
2. Placebo + smoking prevention
counselling
1 × 0.5 mg per day days 1–3, 0.5
mg 2× per day days 4–7 then
1 mg 2× per day thereafter
Self-reported number of cigarettes
smoked per day
Expired CO, cotinine levels and
urges to smoke.
Change in psychiatric
symptoms (PANSS, SANS,
Calgary Depression Scale)
Adverse events
Weiner
2011 [25]
RCT
9 Clinically stable adult outpatients
with DSM IV schizophrenia or
schizoaffective disorder for 3 years
who smoke ≥10 and scored ≥4
on FTND.
United States
Ethnicity and gender not reported.
1. Varenicline (1 mg 2× day) + individual
smoking cessation counselling (ALA)
2. Placebo + individual smoking
cessation counselling (ALA)
Smoking cessation at 12 weeks
defined by expired CO < 10 at
last 4 study visits.
Change in CO
Change in psychiatric
symptoms (BPRS)
Adverse events
Williams
2012 [27]
RCT
128 adult outpatients with DSM IV
schizophrenia or schizoaffective
disorder with stable symptoms
who Smoke ≥15 and scored ≥7
on the contemplation ladder
indicating a willing ness to quit
in the next month and with no
smoking abstinence in the last
3 months
United States and Canada
76% male, 59% white.
1. Varenicline
2. Placebo
1 × 0.5 mg per day days 1–3, 0.5
mg 2× per day days 4–7 then 1 mg
2× per day thereafter
7 day point prevalence abstinence
at 12 and 24 weeks verified by
expired CO <10 ppm.
Number of cigarettes per day
Change in psychiatric
symptoms (SAS, C-SSRS,
CGI, PANSS)
Adverse events
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Table 1 Study characteristics (Continued)
Wu
2012 [37]
RCT
5 psychiatrically stable DSM-IV
bipolar disorder I or II on a
stable dose of mood stabliser,
smoking ≥10 cigarettes per day.
Outpatients
40% male, 100% white
1. Varenicline (1 mg 2× day) + smoking
cessation counselling (group)
2. Placebo + smoking cessation
counselling (group)
Smoking cessation verified by
expired CO >10 ppm at 10
weeks and 6 months
Adverse events
Nicotine Replacement Therapy (NRT) studies
Chen
2013 [29]
RCT
184 adult inpatients who were
regular daily smokers with DSM-IV
schizophrenia or schizoaffective
disorder with stable symptoms.
Taiwan93% male, ethnicity not stated.
1. High dose NRT (31.2 mg for 4
weeks then 20.8 mg for 4 weeks)
2. Low dose NRT (20.8 mg for 8 weeks)
7 day point prevalence self report
verified by expired CO <10 ppm at
5 weeks and 8 weeks
Number of cigarettes smoked
per day
FTND
Change in psychiatric
symptoms (PANSSS, SAS)
Dalak
1999 [11]
RCT (within
subject crossover)
19 male veteran outpatients with
DSM III schizophrenia, schizoaffective
disorder
Smoking ≥20 cigarettes per day
on a stable antipsychotic regime.
United States
100% male, 60% white.
1. Nicotine patches (22 mg per day)
2. Placebo patches
Nicotine blood level
Expired CO
Cotinine blood level
Change in psychiatric
symptoms (BPRS, SANS,
HAM-D)
Adverse events
Gallagher
2007 [20]
RCT
181 stable adult outpatients with
DSM-IV schizophrenia or schizoaffective
disorder, smoking ≥10 cigarettes per
day for 3 years or more with expired
CO ≥ 10 ppm after 15 min smoke free.
United States
52% male, 76% white.
1. Contingent reinforcement
(up to $480)
2. Contingent reinforcement
(up to $480) + NRT patch (21 mg)
3. Self-quit group
Smoking cessation at week 20
and week 36 (Cotinine ≤15
ng/ml or expired CO ≤ 10 ppm)
FTND
Change in psychiatric
symptoms (BSI)
AIMS abnormal involuntary movement scale; ALA American Lung Association; BDI Beck Depression Index; BPRS Brief Psychiatric Rating Scale; CBT cognitive behaviour therapy; CGI-S Clinical Global Impression- Severity
of Illness Scale; CO carbon monoxide; C-SSRS Columbia Suicide Severity of Illness Scale; DSM Diagnosis and Statistical Manual; Ham-D Hamilton Depression Rating Scale; FTND Fagerstrom Test fro Nicotine Dependence;
ICD International Classification of Disease; MADRS Montgomery-Asberg Depression Scale; MNWS Minnesota Withdrawal Scale-Revised; NRT nicotine replacement therapy; PANSS: Positive and Negative Syndrome Scale;
SANS Scale for Assessment of Negative Symptoms; SAS Simpson Angus Scale; SF-12 21 item Short Form Survey on general functioning; SRP Sustained Release Preparation; p.p.m. parts per million; STAI State Trait Anxiety
Inventory; UPDRS Unified Parkinson’s Disease Rating Scale; WEPS Webster Extrapyramidial Movement Scale; WISDM Wisconsin Inventory of Smoking Dependence Motives; YMRS Young Mania Rating Scale
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SMI and three studies investigated the effects of contingent
reinforcement (i.e., providing people with cash incentives if
they had remained abstinent from smoking at defined time
points).
Of the nine trials (involving 306 participants in total)
which explored the effects of bupropion, five tested bupro-
pion plus group therapy versus placebo plus group therapy
[13, 14, 17, 22, 26], two tested bupropion plus group ther-
apy plus NRT versus placebo plus group therapy plus NRT
[19, 21] one tested bupropion plus smoking cessation coun-
selling versus placebo plus smoking cessation counselling
[30]. The final study employed a factorial design testing
contingent plus bupropion versus non-contingent plus
bupropion versus contingent plus placebo versus non-
contingent plus placebo [24]. Tidey did not report abstin-
ence therefore was not included in the meta-analysis.
The addition of varenicline to a range of interventions
in the control arm was tested in six trials (313 partici-
pants in total). Of these six trials, four tested varenicline
plus smoking cessation counselling versus placebo plus
counselling [30, 31, 35, 37], one tested varenicline plus
group therapy versus placebo plus group therapy [25],
and one tested varenicline versus placebo [27].
Five studies explored the effects of a smoking cessation
programme designed for people with SMI (638 participants):
two studies compared the smoking cessation programme to
usual care [18, 33], one explored a specialist programme
plus NRT versus a standard smoking programme plus NRT
[12], one study compared a specialist programme with
medication management [23], and one study compared
motivational interviewing with personalised feedback with
interactive education with no personalisation [36].
Smoking cessation counselling, whether part of the inter-
vention being tested or part of the control arm, consisted of
a range of behaviour change techniques delivered in a var-
iety of formats e.g. face-to-face one-to-one sessions, face-
to-face group sessions or one-to-one sessions delivered via
telephone. It is important to note that in the trials of vare-
nicline and bupropion, where smoking cessation counsel-
ling was delivered, the same programme was delivered in
both the medication (varenicline or bupropion) arm of the
trial as in the usual care arm of the trial. Therefore it is
unlikely that the smoking cessation counselling component
of the study had any bearing on the study results. In the
majority of the trials the exact content, in terms of the
behaviour change techniques employed in the smoking
cessation counselling, was insufficiently described.
No studies were identified exploring the effectiveness
of very brief advice or the effectiveness of electronic
cigarettes.
Methodological quality
Table 2 Summarises the risk of bias in the included studies.
Overall the studies were at high risk or unclear risk of bias
aside from Smith 2015 [34] and Smith 2016 [35] which were
both at low risk of bias. Overall there was a lack of detail
given in the descriptions of key study design features which
has led to studies being deemed at an unclear risk of bias.
For those studies that were assessed as having an unclear
risk of bias the issue may be with the reporting as opposed
to actual study conduct. The risk of bias was assessed by
two reviewers and there were only few disagreements which
were simply resolved by discussion until consensus was
reached. Discussion with 3rd reviewer not necessary in any
of the instances.
Smoking abstinence
Risk ratio (pooled) for point prevalence abstinence at short,
medium and long term for studies exploring the addition of
bupropion (Fig. 2), varenicline (Fig. 3) and a specialist
smoking intervention for people with SMI (Fig. 4) were
calculated. Funnel plots are not included in this review
because we identified less than 10 studies eligible for
inclusion in the meta-analyses.
Bupropion versus placebo
Eight trials that tested the addition of bupropion to a range
of interventions in the control arm reported abstinence data.
These studies were pooled to judge whether the addition of
bupropion offered any additional benefit (Fig. 2). Pooling
this data using a fixed-effects meta-analysis showed that the
addition of bupropion improved quit rates significantly in
the medium term and long term but not in the short term
(short term RR = 6.42 95% CI 0.82–50.07; medium term
RR = 2.93 95% CI 1.61–5.34; long term RR = 3.04 95% CI
1.10–8.42). The median duration of the short term compari-
son was four weeks, 3.5 months for the medium term com-
parison, and 11.75 months for the long term comparison.
There was no evidence of between study heterogeneity
(I2 = 0%).
Varenicline versus placebo
Five of these studies were pooled to evaluate whether the
addition of varenicline offered any additional benefit (Fig. 3).
Pooling this data using a fixed-effects meta-analysis showed
that the addition of varenicline improved quit rates signifi-
cantly in the medium term (RR = 4.13 95% CI 1.36–12.53),
median time-point six months. None of these five studies
gave long term quit data. There was no evidence of between
study heterogeneity (I2 = 0%). Participants in these studies re-
ceived varenicline for between eight and 12 weeks. Removing
the monotherapy study [27] from the meta-analysis did not
substantially change the results and there was no overall
change in heterogeneity (RR = 3.62 95% CI 0.68–38.69).
Specialist smoking cessation programme
The results from the studies exploring smoking cessation
interventions were mixed in terms of results when
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compared to those exploring the effectiveness of smoking
cessation medication. Whilst some studies reported positive
findings others reported negative findings. This may be due
to differences in the smoking cessation intervention being
tested. It may be that some interventions or components of
interventions are more effective than other smoking cessa-
tion interventions, however this cannot be certain. The set-
ting, delivery mode and who delivers the intervention may
also have some influence of the effectiveness of the
intervention.
Four studies gave abstinence data, three of which gave
medium term data and long term data and one gave long
terms data only. These studies were pooled to assess
whether a specialist programme offered any additional
benefit (Fig.4). Pooling this data using a fixed-effects
meta-analysis showed that there was no evidence of bene-
fit for the specialist smoking cessation programme in the
medium term (RR = 1.32 95% CI 0.85–2.06) or in the long
term (RR = 1.33 95% CI 0.85–2.08). Median duration of
comparison was six months in the medium term and
12 months in the long term. None of these five studies
gave short term quit data. There was no evidence of be-
tween study heterogeneity (I2 = 0%).
Secondary outcomes
Change in psychiatric symptoms
Of the included studies, 22 used one or more validated
symptom scales to ascertain whether psychiatric symptoms
had altered during the course of the trial (Table 3). None of
the studies that tested outcomes for significance found any
Table 2 Risk of bias of included studies
Adequate sequence
generation
Allocation
concealment
Blinding of participants
and personnel
Blinding of
outcome
assessment
Incomplete
outcome data
addressed
Free of selective
reporting
Free of
other bias
Overall
Baker 2006 [18] Unclear High Risk High Risk Low Risk Low Risk Low Risk Low risk High risk
Baker 2015 [32] Unclear Unclear High Risk Low Risk High Risk Low Risk Low risk High
Chen 2013 [29] Unclear Unclear Unclear Unclear Low Risk Unclear Low risk Unclear
Chengappa
2014 [31]
Unclear Unclear Low Risk Low Risk Unclear Low risk Low risk Unclear
Dalak 1999 [11] Unclear Unclear Unclear Unclear Unclear High risk High risk Unclear
Evins 2001 [13] Unclear Unclear Unclear Unclear Low Risk Unclear Low risk Unclear
Evins 2005 [17] Unclear Unclear Unclear Unclear Unclear Unclear High risk Unclear
Evins 2007 [19] Unclear Unclear Unclear Unclear Unclear Unclear Low risk Unclear
Fatemi 2013 [30] Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Gallagher
2007 [20]
Unclear Unclear High Risk High Risk High risk Unclear Low risk High
George 2000 [12] Unclear Unclear High Risk Unclear Unclear Unclear High risk High
George 2002 [14] Unclear Unclear Low Risk Low Risk Low risk Unclear Low risk Unclear
George 2008 [21] Unclear Unclear Unclear Unclear High risk High risk Low risk High
Gilbody 2015 [33] Low Risk Low Risk High Risk High Risk Low Risk High Risk Low risk High
Steinberg
2003 [15]
Unclear Unclear High Risk Low Risk High Risk Unclear Low risk High
Tidey 2011 [24] High Risk High Risk Low Risk Low Risk High Risk Unclear High risk High
Weinberger
2008 [22]
Unclear Unclear Unclear Unclear High Risk Unclear High risk High
Weiner 2011 [25] Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Weiner 2012 [26] Unclear Unclear Unclear Unclear Low risk Unclear Low risk Unclear
Williams 2010 [23] Unclear Unclear High Risk Low Risk High Risk Unclear High risk High
Williams 2012 [27] Unclear Unclear Low Risk Low Risk Low Risk Low Risk Unclear Unclear
Wing 2012 [28] Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Wu 2012 [37] Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Steinberg
2016 [36]
Unclear Unclear High risk Low risk Low risk Unclear High risk High
Smith 2015 [34] Low risk Low risk Low risk Low risk Unclear Unclear Low risk Low risk
Smith 2016 [35] Low risk Low risk Low risk Low risk Low risk Low risk Unclear Low risk
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significant worsening of psychiatric symptoms in the inter-
vention group and only one study found a significant wors-
ening of cognitive score in the intervention group
compared to placebo [17]. Therefore it does not appear that
smoking cessation interventions worsened psychiatric
symptoms however due to heterogeneity between the
symptom scales and time points used no meta-analysis was
conducted.
Only one study that included participants with bipolar
disorder reported on the significance of any change in
psychiatric symptoms (not significant). The rest of the
studies that reported secondary outcome included par-
ticipants with schizophrenia and schizoaffective disorder.
Change in BMI
Change in BMI was not routinely measured in the
included studies and only two studies listed BMI as one
of their outcomes [31, 33]. Of these only one study
reported change in BMI therefore no meta-analysis was
conducted.
Adverse events
Of the included studies 14 included some reporting of
adverse events (Table 3), although in four of these stud-
ies this was not fully reported. No standardised method
for reporting adverse events was used and some studies
differentiated between serious adverse events and ad-
verse events whereas some did not.
Cost effectiveness
Only one study [33] set out to explore the cost-
effectiveness of the intervention. This study demonstrated
that it was feasible to carry out a cost-effectiveness analysis
of a bespoke smoking cessation intervention compared to
usual care however as it was a pilot study it was not suffi-
ciently powered for any firm conclusions could be drawn.
Discussion
Since our previous review there has been an increase in
the evidence base of smoking cessation interventions for
people with SMI. Previously we identified seven studies
Fig. 3 Addition of varenicline
Fig. 2 Addition of bupropion
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meeting the inclusion criteria, in this review we have in-
cluded 26 studies, 19 more than our previous review, in-
dicating that this is a rapidly developing field. Despite
the increase in the number of studies exploring the ef-
fectiveness of smoking cessation interventions for people
with SMI, the studies are still generally of a small size
and underpowered to detect a difference between the
intervention and control. Overall studies were at high or
unclear risk of bias with only two of the most recent
studies being at low risk of bias [34, 35].
In line with the results of our previous review, this up-
dated review indicates that people with SMI can quit
smoking and the same interventions that work for
people in the general population work for people with
SMI e.g. the use of varenicline, bupropion or NRT to
support a quit attempt. The addition of bupropion gives
a similar risk ratio at both medium and long term to
that of our previous review [7]. In our previous review
we calculated an RR = 2.76 (95% CI 1.48–5.16) CI 1.10–
8.42) compared to 3.04 (95% CI 1.10–8.42) for long term
point prevalence. For varenicline our review showed a
slight increase in RR compared to a recent Cochrane re-
view [39] where the RR = 2.27 (95% CI 2.02–2.55) whilst
our meta-analysis gave a medium term RR of 2.93 (95%
CI 1.61–5.34). A recent review of the effectiveness of
varenicline in people with SMI which had slightly differ-
ent inclusion criteria to our review also concluded that
varenicline was clinically superior to placebo in helping
people with SMI [40]. Due to the unclear or high risk of
bias of 24 of the 26 included studies in our review our
results need to be interpreted with some caution.
Point prevalence absolute quit rates at the final time-
point for intervention groups ranged from 1.1 to 75.0%,
and for control groups ranged from 0.0 to 22.9%. In
addition quitting smoking did not appear to worsen par-
ticipants’ mental state. In terms of varenicline and bu-
propion our review indicates that both medications
appear to be effective in the medium terms as an aid to
smoking cessation. A recent large trial comparing out-
comes of people with psychiatric disorder has also found
varenicline and bupropion to be effective with no in-
crease in neuropsychiatric events [41], however this
study was not eligible for inclusion in our review as the
psychiatric cohort was not limited to people with SMI.
The effectiveness of behavioural interventions in helping
people with SMI to quit smoking is currently unclear
and is the subject of on-going study [42].
We identified two studies [29, 35] that included patients
in an inpatient setting, however the majority of the studies
were conducted in a psychiatrically stable population and
it is therefore unclear as in our previous review how far
these findings are generalisable to an acutely unwell popu-
lation. It is important that further studies are conducted
into what works in an acutely unwell population.
The use of e-cigarettes has been increasing in recent
years [43] and a Cochrane review was conducted in 2016
exploring their effectiveness as a smoking cessation aid
[44]. E-cigarettes have been shown to have a similar effect
on quit rate as NRT [45]. However we did not identify any
RCTs that explored the use of e-cigarettes as a smoking
cessation aid for people with SMI. A subgroup analysis of
people who took part in the ASCEND trial was conducted
analysing the results for people with mental disorders
however this was not limited to SMI [46]. This subgroup
analysis indicated that e-cigarettes appear to be as effective
in people with mental disorders as those without mental
disorders. This topic deserves further research and there
is a need for future trials of electronic cigarettes as an aid
to smoking cessation amongst people who use mental
health services.
Only one study investigated the cost effectiveness of a
smoking cessation intervention and this was a pilot
study so no clear conclusions could be drawn [33]. More
trials are needed with a prospective cost effectiveness
analysis. In addition how an intervention may fit into
existing service structures needs to be explored.
Fig. 4 Addition of specialist smoking cessation programme
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Table 3 Outcomes
Change in BMI Change in psychiatric symptoms Adverse events Quit rate (%) intervention (I) control (C)
Complex interventions
Baker 2006 [18, 38]
(including data from
Baker 2010)
Not reported Time-points: 4 months, 7 months,
13 months
CDI: significantly lower score for intervention
group p < 0.001 at all time-points
BPRS: not significant at any time point
SF-12 (mental): significantly lower score for
intervention group p < 0.001 at all
time-points
STAI: significantly lower for intervention
group p < 0.001 at 7 months
Not reported 4 months
I: 22/147 (15.0) C: 9/151 (6.0)
7 months
I: 14/147 (9.5) C: 6/151 (4.0)
13 months
I: 16/147 (10.9) C: 10/151 (6.6)
4 years
I: 13/147 (8.8) C: 17/151 (11.3)
Baker 2015 [32] Not reported Time point 3.75, 12 months
BPRS, BDI, GAF, SF-12 not significant
Not reported 3 months
I: 13/122(10.7) C: 13/113 (11.5)
12 months
I: 8/122 (6.6) C: 7/113 (6.2)
George 2000 [12] Not reported Time-points: 3 months, 8.5 months
AIMS, BDI, PANSS, WEPS: not significant
Not reported 3 months
I: 10/28 (35.7) C: 6/17 (35.3)
8.5 months
I: 3/28 (10.7) C: 3/17 (17.6)
Gilbody 2015 [33] Change in BMI not reported.
Mean BMI at baseline and
12 month reported.
Time points 1,6,12 months
PHQ-9, EQ-5D, SF-12 mental reported
but not tested for significance
21 events of which 12 SAEs,
10 in intervention 2 in usual care
12 months
I: 12/33 (36.3) C: 8/35 (22.9)
Smith 2015 [34] Not reported Time point after final session
PANSS and PYCHRATS no significant
differences
15 AEs in active treatment arm
and 16 in sham treatment arm
Abstinence not reported
Steinberg 2003 [15] Not reported Not reported Not reported Abstinence not reported
Steinberg 2016 [36] Not reported Not reported Not reported 1 month
I: 8/49 (16.3) C: 5/49 (10.2)
Williams 2010 [23] Not reported Time-point 3 months
BDI and PANSS positive and negative
not significant
Not reported 3 months
I: 7/45 (15.6) C: 11/42 (26.2)
6 months
I: 7/45 (15.6) C: 8/43 (18.6)
12 months
I: 6/45 (13.3)
C: 6/43 (14.0)
Wing 2012 [28] Not reported No detail on secondary outcomes given Not reported Abstinence not reported
Bupropion studies
Evins 2001 [13, 16]
(including data from
Evins 2004)
Time-points 3 months, 6 months
AIMS, SANS, SAS: not significant
BPRS (total): significant decrease
intervention group 0–3 months
(p = 0.03) and 3–6 months (p = 0.02)
No adverse events 1 months I: 3/9 (33.3) C: 1/9 (11.1)
3 months
I: 1/9 (11.1) C: (0/9) (0.0)
6 months
I: 1/9 (11.1) C: 0/9 (0.0)
24 months
I: 2/9 (22.2) C: 2/9 (22.2)
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Table 3 Outcomes (Continued)
BPRS (+ve symptoms): significant decrease
intervention group 0–3 months (p = 0.03).
Not significant 3-6 m.
HAM-D: significant increase for placebo
group 0–3 months (p < 0.01).
Not significant 3-6 m.
HAS: not significant
Evins
2005 [17]
Not reported Time-points 3 months
Barnes Akathisia Scale: not significant
HAM-A, HAM-D, SANS, SAS, WEPS,
PANSS (total): not significant
PANSS (subscale); significant increase in
excitement score placebo versus intervention
group (P = 0.017)
Significant decrease cognitive score
intervention versus placebo (P = 0.029)
Other subscales not significant
3 events requiring withdrawal,
1 in the intervention, 2 group
unknown
1 months
I: 9/25 (36.0) C: 2/28 (7.0)
3 months
4/25 (16.0) c: 2/28 (0.0)
3.5 months
I: 2/25 (8.0) C: 1/28 (3.6)
6 months
I: 1/25 (4.0) C: 1/28 (3.6)
Evins
2007 [19]
Not reported Time-points: 3 months
AIMS, BDI, SANS, STAI, HAM-D, PANSS:
not significant
Barnes Akathisia Scale: significantly lower
in intervention group (P = 0.005)
SAS: significantly lower score in the intervention
group (P = 0.016)
No SAEs 2 months*
I: 13/25 (52.0) C:5/26 (19.2)
3 months*
I: 9/25 (36.0) C: 5/26 (19.2)
6 months*
I: 5/25 (20.0) C: 2/26 (7.7)
15 months*
I: 3/25 (12.0) C: 2/26 (7.7)
Fatemi
2013 [30]
Not reported Time point: 3 months
Significant positive correlation between serum
cotinine levels and BPRS total score (p = 0.014),
BPRS +ve subscale score (p = 0.002), SAPS total
composite score (p = 0.02) and SAPS delusion
subscale score (p = 0.013)
Not fully reported Abstinence not reported
George
2002 [14]
Not reported Time-points 2.5 months, 8.5 months
AIMS, BDI, WEPS: not significant
PANSS: significant decrease in
intervention group for negative
symptoms (P < 0.05; general
positive subscales not significant
Not reported 2.5 months
I: 8/16 (50.0) C: 2/16 (12.5)
8.5 months
I: 3/16 (18.8) C: 1/16 (6.3)
George
2008 [21]
Not reported Time-points: 2.5 months, 6.75 months
BDI, PANSS: not significant
No SAEs 2.5 months
I: 10/29 (34.5) C: 3/29 (10.3)
6.75 months
I: 4/29 (13.8) C: 0/29 (0.0)
Weinberger
2008 [22]
Not reported No details given on secondary outcomes Not fully reported 2.5 months
I: 1 /2 (50.0) C: 0/3 (0.0)
Weiner
2012 [26]
Not reported Time-points: 2 weeks, 1 month,
2 months and 3.5 months
BPRS, SANS: not significant
5 SAEs in the intervention group
and 2 in the placebo group
3.5 months
I: 8/24 (33.3) C: 3/22 (13.6)
Not reported Time-points 1,2, 3, 4 weeks Abstinence not reported
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Table 3 Outcomes (Continued)
Tidey
2011 [24]
PANSS, UPDRC ad AIMS not significant Not fully reported incidence of
specific AEs reported but not all
Varenicline studies
Chengappa
2014 [31]
Mean weight gain Time-points 3, 6 months
Scores for MADRS, YMRS, HARS and
CGI reported but not tested for significance.
6 SAEs in the intervention group
and 4 in the placebo group
3 months
I: 15/31 (48.4) C: 3/29 (10.3)
6 months
I: 6/31(19.4) C: 2/29 (6.9)
Smith
2016 [35]
Not reported Time-point 8 weeks
Scores for PANSS, and SANS not
significant when corrected for multiple
comparisons.
Comparisons made between number
of AEs in both groups. Concluded that
no AE involving emergent psychiatric
symptoms could be attributed to
varenicline.
8 weeks
I:7/42 (16.7) C: 4/45 (8.9)
Weiner
2011 [25]
Not reported Time-points 3 months
BPRS +ve items, anxiety/depression
not significant
8 side effects in the intervention
group 2 in the placebo group
4 months
I: 3 /4 (0.75) C: 0/4 (0.0)
Williams
2012 [27]
Not reported Time-points: 3, 6 months
PANSS not significant
9 SAEs in the intervention group
and 4 in the placebo group
3 months
I: 16/84 (19.0) C: 2/43 (4.7)
6 months
I: 10/84 (11.9) C: 1/43 (2.3)
Wu 2012 [37] Not reported Time-points 2.5 months
Psychiatric symptoms not significantly
changed
Not fully reported 2.5 months
I: 1/3 (33.3) C: 0/2 (0.0)
6 months
I: 0/3 (0.0) C: 0/2 (0.0)
NRT studies
Chen
2013 [29]
Not reported Time-points: 2 months
PANSS, SAS not significant
Not reported 2 months
I: 1/92 (1.1) C: 4/92 (4.3)
I = high dose C = low dose
Dalak
1999 [11]
Not reported Time-points: day 2
AIMS: significantly increased
score intervention group day 2 (p < 0.05)
BPRS, HAM-D, SANS, SAS: not significant
Assessment for signs of nicotine
toxicity none reported
Abstinence not reported
Gallagher
2007 [20]
Not reported Time points 5, 9 months
BSI not significant
Not reported 5 months
Ia**: 23/60 (38.3) Ib***: 25/60
(41.7) C: 3/60 (5.0)
8.5 months
Ia: 22/60 (36.7) Ib: 26/60 (43.3)
C: 5/60 (8.3)
**Ia = contingent reinforcement *** Ib = Contingent reinforcement plus NRT
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Only one study reported change in body weight and this
was reported as mean change in BMI [31]. Given that weight
gain is associated with the prescription of antipsychotic medi-
cation [47] and the health implications of obesity it is import-
ant that weight change is recorded and reporting in clinical
trials. A recent systematic review demonstrated that whilst
the mean increase in body mass 12 months after stopping
smoking is four to five kilograms there was a wide variation
in body mass change [48] (16% of participants had a reduced
mass and 13% gained more than 10 kg).
The reporting of adverse events was not standardised.
In 12 of the studies included in this review no details of
adverse or serious adverse events were reported. It is im-
portant that adverse events are clearly reported as per
the CONSORT guidelines [49] to allow a judgment to be
made as to whether or not a pharmaceutical smoking
cessation aid is suitable for people with SMI.
Strengths and limitations
A limitation of this review is that it only included articles
that were written in English and this could have resulted
in the exclusion of potentially important studies. The fact
that all the titles and abstracts were not double screened is
a possible limitation however the fact that both authors
who screened the initial 10% of titles and abstracts were in
agreement over which studies should go forward to full
text review reduces the possibility that potentially suitable
studies were missed. In addition reference lists of previous
reviews of smoking cessation strategies were searched.
There is currently a paucity of e-cigarette research. This is
a technology that is rapidly evolving and where there has
been uptake in the use of e-cigarettes in advance of rando-
mised trials being conducted. However, a strength of this
review compared to our previous review is that it includes
the use of e-cigarettes as a smoking cessation aid.
Due to the heterogeneity of the scales used to assess psy-
chiatric symptoms it was not possible to conduct a detailed
analysis of the results or a meta-analysis. We have therefore
summarised whether or not studies found a significant
change in psychiatric symptoms and concluded that no sig-
nificant worsening was found on giving up smoking.
It is possible that the results of this review are at risk
of publication bias. To minimise the possibility of publi-
cation bias we checked trial registries to determine
whether there were any trials registered that had not
been published. Funnel plots are not included in this re-
view because we identified less than 10 studies eligible
for inclusion in the meta-anayses.
Recommendations for future research
It is currently unclear what proportion of people with
SMI will engage with a smoking cessation intervention
and trials are needed that will explore the use of very
brief advice to encourage people with SMI to seek help
with smoking. It is also recommended that the use of e-
cigarettes as a smoking cessation aid for people with
SMI be explored in future high quality RCTs.
Conclusions
Despite evidence for the effectiveness of smoking cessa-
tion interventions for people with SMI the percentage of
people with SMI who smoke in the UK still remains
higher than the percentage of people without SMI who
smoke.
In addition to our previous findings regarding the
effectiveness of bupropion in helping people with SMI
to quit smoking there is now trial based evidence to
demonstrate that varenicline appears to be effective in
helping people with SMI to quit smoking.
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